Invesco India Pharma & Healthcare Fund NFO Launched
By Market Desk
Invesco India launches its Pharma and Healthcare Fund NFO on Aug 18, 2026. Invest ₹1,000+ in this equity fund aiming to track index returns.
Invesco India has launched its new fund offer (NFO) for the Invesco India Pharma and Healthcare Fund Regular Growth, aiming to mirror the total return of its underlying index before expenses. This investment objective, however, comes without a guarantee of achievement, as is standard in market-linked products.
Investors keen on the sector can subscribe to the NFO starting August 18, 2026. The subscription window will remain open for a defined period, closing on September 1, 2026, marking a specific timeframe for initial investments.
The fund’s Net Asset Value (NAV) is set at 10, providing a clear entry point for prospective investors. A minimum investment of ₹1,000 is required to participate in this Growth scheme type.
Categorized as an Equity fund, the Invesco India Pharma and Healthcare Fund includes an exit load of 0.50%. This charge applies to redemptions made within a specific holding period, influencing short-term liquidity decisions for unitholders.
Aditya Khemani serves as the fund manager for this new offering, having taken charge in September 2026. His leadership will guide the fund’s strategy within the dynamic pharmaceutical and healthcare sectors.
The launch signifies Invesco’s focused approach to specific market segments, offering investors a targeted route into India’s growing healthcare and pharmaceutical industries. Market participants will monitor its performance against the stated objective and underlying index.